Oral Bisphosphonate Did Not Improve Prognosis for Patients With Breast Cancer
- Patients treated with dose-dense chemotherapy did not show signs of improvement with oral bisphosphonates.
- Other studies have shown bisphosphonates are beneficial for patients receiving endocrine treatment.
- Results do not confirm the use of bisphosphonates in the adjuvant setting.
SAN ANTONIO - Results from a German study demonstrated no improvement in disease-free survival among patients with breast cancer who were treated with dose-dense chemotherapy and the bisphosphonate ibandronate.
Volker Möbus, Ph.D., head of the department of obstetrics and gynecology at Klinikum Frankfurt Höchst GmbH in Frankfurt, presented the results from the German Adjuvant Intergroup Node Positive (GAIN) Study, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.
Möbus and his colleagues randomly assigned 3,023 patients with breast cancer to two different chemotherapy regimens and then further assigned them to 50 milligrams of oral ibandronate or observation. After a median follow-up of 38.7 months, "we found no significant difference between groups in the primary endpoint" of disease-free survival, Möbus said.
He described these results as "disappointing" compared with other studies. In the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer (AZURE) trial, for example, Möbus said that the subgroup of postmenopausal patients showed an improvement in recurrence-free and overall survival.
* read more*
2008, Left, Stage IIIB, Grade 3, 7/14 nodes, ER+/PR+, HER2-
5/2016, Stage IV, metastasized to liver, ER+/PR+, HER2-
Log in to post a reply